Riskpilot← Back to searchSign inGet full accessNordic Biomarker AB
ABActiveOrg 5567363626Vildmannavägen 1Manufacture of other chemical products n.e.c. · NACE 2059Est. 200753 employees
Revenue 2024
SEK 132,4M
+8% vs 2023
EBITDA margin
7.2%
+135% vs 2023
Equity ratio
73.7%
Financial strength
Net profit 2024
SEK -4,8M
+88% vs 2023
| Revenue | SEK 132,4M | +8% |
| EBITDA | SEK 9,5M | +135% |
| Net profit | SEK -4,8M | +88% |
| Total assets | SEK 168,8M | +3% |
| Equity | SEK 124,3M | +65% |
| Employees | 53 | — |
Legal name
Nordic Biomarker AB
Org number
5567363626
Legal form
Aktiebolag
NACE code
2059 · Manufacture of other chemical products n.e.c.
Founded
24 augusti 2007
Share capital
SEK 150 000
Employees
53 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av ledamoten i förening med en av Conradsson, Johan Fredrik Kristiansson, Erik Richard
Company purpose
Bolagets verksamhet ska vara att utveckla, tillverka och marknadsföra reagens och anlysinstrument som används för koagulationsdiagnostik och därmed förenlig verksamhet.
Address
Vildmannavägen 1
Email
info@nordicbiomarker.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 79 748 | 94 659 | 129 627 | 122 335 | 132 367 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 27 128 | 2 200 | −14 454 | −27 102 | 9 477 |
| Depreciation & amort. | −1 421 | −3 573 | −9 069 | −11 618 | −16 281 |
| EBIT | 25 707 | −1 373 | −23 523 | −38 720 | −6 804 |
| Net financials | 206 | −194 | −1 788 | −2 003 | −540 |
| Profit before tax | 18 886 | 933 | −18 411 | −39 243 | −6 294 |
| Tax | −4 075 | −223 | −0 | 543 | 1 468 |
| Net profit | 14 811 | 710 | −18 411 | −38 700 | −4 826 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 162 434 | 178 324 | 208 098 | 163 333 | 168 773 |
| Equity | 107 487 | 106 467 | 135 293 | 75 459 | 124 303 |
| Long-term debt | 27 246 | 35 905 | 0 | 0 | 0 |
| Short-term debt | 27 701 | 34 071 | 71 158 | 80 304 | 38 367 |
| Total debt | 54 947 | 69 976 | 71 158 | 80 304 | 38 367 |
EBITDA margin
7.2%
This company
15.8%
Market median
-54% vs market
20202024
Equity ratio
73.7%
This company
38.2%
Market median
+93% vs market
20202024
Return on equity
-3.9%
This company
18.4%
Market median
-121% vs market
20202024
Net profit margin
-3.6%
This company
8.1%
Market median
-144% vs market
20202024
Asset turnover
0.78×
This company
1.12×
Market median
-30% vs market
20202024
Debt / equity
0.36×
This company
0.62×
Market median
+42% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
RA Chief Executive Officer | Chief Executive Officer | 2021 |
JF External Signatory | External Signatory | 2022 |
JA Chief Auditor | Chief Auditor | 2022 |
ER External Signatory | External Signatory | 2022 |
| Former (3) | ||
CL External Signatory | External Signatory | 2023 – 2023 |
JM Chief Auditor | Chief Auditor | 2023 – 2023 |
CG Chief Auditor | Chief Auditor | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2021 | |
| Former (4) | ||
| Deputy Board Member | 2023 – 2023 | |
| Chairman | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nordic Biomarker Holding AB
Nordic Biomarker AB Board members of Nordic Biomarker AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Cecilia Linnea Waldehorn | External Signatory | 0 companies |
| Johanna Margareta Eklöf | Chief Auditor | 0 companies |
| Carl Gustaf Mikael Fredstrand | Chief Auditor | 0 companies |
| Rikard Albert Rodén | Chief Executive Officer | 0 companies |
| Johan Fredrik Conradsson | External Signatory | 0 companies |
| Johan Anders Pettersson | Chief Auditor | 0 companies |
| Erik Richard Kristiansson | External Signatory | 0 companies |
| Anna Katharina Gimlander | Deputy Board Member | 0 companies |
| Eva Kristina Isaksson | Deputy Board Member | 0 companies |
| Bill Tunbrant | Chairman | 0 companies |
| Bernt Gunnar Pohl | Board of Directors | 0 companies |
| Claes Gustav Tyko Blanche | Board of Directors | 0 companies |